<DOC>
	<DOCNO>NCT00536640</DOCNO>
	<brief_summary>This study want determine activity non chemotherapy first line biological treatment Erlotinib/Bevacizumab Gemcitabine-Cisplatin/Bevacizumab patient diagnosis non-squamous advanced Non Small Lung Cancer .</brief_summary>
	<brief_title>Inoperable Non-Squamous NSCLC Stage III/IV : A Randomised Phase II Study With Bevacizumab Plus Erlotinib Or Gemcitabine/Cisplatin Plus Bevacizumab</brief_title>
	<detailed_description>Prospective , randomized multi-center , open label phase II study determine activity non-chemotherapy first line biological treatment Erlotinib/Bevacizumab Gemcitabine-Cisplatin/Bevacizumab patient diagnosis non-squamous advanced Non-Small-Lung-Cancer . - Duration treatment/patient : 1,5 year - Follow Up : ≈ 6 month - Planned number patient : 220 treat patient ( 110 patients/arm )</detailed_description>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Histological confirm NonSmall Cell Lung Cancer treat within defined radiological field Tumor stage IIIB ( pleural effusion pericardial effusion include ) IV The following histological tumor type eligible : Adenocarcinoma ( include adenocarcinoma bronchioloalveolar differentiation ) Large Cell Carcinoma ( include large cell carcinoma neuroendocrine differentiation ) Mixed Cell Carcinoma without small cell fraction without predominant squamous cell fraction ( &lt; 50 % ) undifferentiated nonsmallcellcarcinoma No previous chemotherapy within last five year At least 4 week since last major surgery Age ≥ 18 year ECOG &lt; = 2 Adequate hematological laboratory parameter Hemoglobin ≥ 10 g/dl WBC ≥ 3.000/µl Platelets ≥ 100.000/µl Adequate hepatic laboratory parameter Bilirubin &lt; = 2,0 mg/dl AST ( GOT ) &lt; = 2,5 x ULN patient without liver metastasis AST ( GOT ) &lt; = 5 x UNL patient liver metastasis ALT ( GPT ) &lt; = 2,5 x ULN patient without liver metastasis ALT ( GPT ) &lt; = 5 x UNL patient liver metastasis Adequate renal laboratory parameter Creatinine &lt; = 1,5 mg/dl Creatinine Clearance &gt; 60 ml/min Adequate plasmatic blood coagulation INR &lt; = 1,5 PTT &lt; = 1,5 x ULN Normal cardiac function define LVEF &gt; 49 % ( echocardiography ) Electrocardiogram without significant sign cardiac arrhythmias Provision inform consent accord local regulatory requirement prior protocol specific treatment Measurable lesion accord RECISTCriteria 's Negative pregnancy test woman childbearing potential unless postmenopausal baseline . ( Postmenopausal woman must amenorrheic least 12 month consider non childbearing potential ) Women child bear potential must willing use acceptable method avoid pregnancy least one month study start . Examples : oral contraceptive ( sole application oral contraceptive sufficient ) , diaphragm pessary , intrauterine device ( spiral ) , condom plus diaphragm pessary plus spermicide Histologic confirm squamous cell carcinoma Pregnancy lactation period Tumor extension treatable radiotherapy Current clinical sign symptom brain and/or leptomeningeal metastasis confirm CT MRI brain scan Evidence tumor invade abut major blood vessel Other coexist malignancy malignancy diagnose within last 5 year exception CIS cervix nonmelanomatous skin cancer . Patients curatively treat free disease least 5 year discuss Principal Investigator ( LKP ) inclusion Any previous chemotherapy within last five year Any radiotherapy exception follow situation : concomitant small field radiotherapy case solitary bone metastasis solitary metastasis case large field radiotherapy multiradiation field due multiple bone metastases metastasis . The application study medication must delay least 24 h ( last radiotherapy ) case radiotherapy primary tumor trial therapy employ radiotherapy end least 6 week ago new tumor progression clearly document Treatment investigational new drug , currently within last 28 day , and/or participation another clinical trial , currently last 12 week , and/or previous participation study A history presence CNS disorder psychiatric disability judge Investigator clinically significant and/or interfere compliance oral drug intake Patients clinically significant disease opinion investigator likely put patient risk interfere evaluation patient 's safety study outcome . This include , limited : Any known significant ophthalmologic abnormality surface eye ( use contact lens recommend ) Immediate need therapeutic intervention ( e.g . : upper inflow congestion poststenotic pneumonia ) Clinically significant cardiac disease ( e.g . rightsided heart failure , symptomatic coronary artery disease cardiac arrhythmia well controlled medication ) myocardial infarction within last 6 month pleural effusion pericardial effusion need intervention Uncontrolled hypertension Non healing wound , ulcer bone fracture Fresh thrombosis therapy anticoagulant Hemorrhagic diathesis , Hemophilia A , Hemophilia B Implantation central vein catheter ( ProtCatheter ) within 24 h prior application study medication Present hemoptysis CTC grade history hemoptysis CTC grade within 3 month prior study start Peritoneal carcinomatosis History abdominal fistula , gastrointestinal perforation intraabdominal abscess within 6 month prior study start Interstitial pneumonia extensive symptomatic interstitial fibrosis lung Pleural effusion ascites , cause respiratory compromise Any active uncontrolled infection Organ allograft History mental disease condition interfere patient 's ability understand requirement study intake study medication accord study protocol Inability swallow pill Current recent ( within 10 day first dose study medication ) use coumadin/warfarin marcumar/phenprocoumon therapeutic purpose Prophylactic use low molecular weight heparin allow Current recent ( within 10 day first dose study medication ) use ASS Dosage &gt; 325 mg/day Current recent ( within 10 day first dose study medication ) use Plavix/Clopidogrel Alcohol drug abuse Known hypersensitivity study drug Presence tracheobronchial fistula fistulization organ system like gastrointestinal fistula fistulization urogenital tract</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>Non Small Cell Lung Carcinoma ( NSCLC Stage III IV )</keyword>
</DOC>